Bristol-Myers Squibb
BMY
$48.52
Share price
1.80%
Change (1 day)
18.75%
Change (1 year)
Categories
P/S ratio for Bristol-Myers Squibb (BMY)
P/S ratio as of July 2025 (TTM): 2.07
According to Bristol-Myers Squibb's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.64. At the end of 2025 the company had a P/S ratio of 2.56.
P/S ratio history for Bristol-Myers Squibb from 2001 to 2025
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2025 | 2.56 | 5.85% |
| 2024 | 2.42 | 4.41% |
| 2023 | 2.32 | -30% |
| 2022 | 3.31 | 11.08% |
| 2021 | 2.98 | -9.5% |
| 2020 | 3.30 | -39.73% |
| 2019 | 5.47 | 46.19% |
| 2018 | 3.74 | -22.49% |
| 2017 | 4.83 | -3.97% |
| 2016 | 5.03 | -27.14% |
| 2015 | 6.90 | 12.28% |
| 2014 | 6.15 | 15.44% |
| 2013 | 5.32 | 76.57% |
| 2012 | 3.01 | 7.25% |
| 2011 | 2.81 | 21.74% |
| 2010 | 2.31 | -10.66% |
| 2009 | 2.58 | 15.66% |
| 2008 | 2.23 | -21.96% |
| 2007 | 2.86 | -0.67% |
| 2006 | 2.88 | 23.12% |
| 2005 | 2.34 | -17.55% |
| 2004 | 2.84 | 7.6% |
| 2003 | 2.64 | 5.74% |
| 2002 | 2.50 | -52.16% |
| 2001 | 5.22 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.36 | 13.96% | 🇺🇸 USA |
 Merck MRK | 3.33 | 60.84% | 🇺🇸 USA |
 Eli Lilly LLY | 14.6 | 604.27% | 🇺🇸 USA |
 Novartis NVS | 4.61 | 122.76% | 🇨🇭 Switzerland |
 Sanofi SNY | 2.53 | 22.57% | 🇫🇷 France |
 AstraZeneca AZN | 4.06 | 96.16% | 🇬🇧 UK |
 Johnson & Johnson JNJ | 4.25 | 105.63% | 🇺🇸 USA |
 AbbVie ABBV | 6.04 | 192.20% | 🇺🇸 USA |
 Amgen AMGN | 4.73 | 128.64% | 🇺🇸 USA |
 Biogen BIIB | 2.01 | -2.72% | 🇺🇸 USA |